| AMGN |
Amgen Inc. |
92%
|
Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection af… |
| AMGN |
Amgen Inc. |
92%
|
Reciprocal relationship from AMGN graph: Reciprocal relationship from PODD graph: Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® k… |
| DISTRIBUTOR-A |
DISTRIBUTOR-A |
92%
|
The percentages of accounts receivable trade for customers that represent 10% or more of total accounts receivable trade were as follows: March 31, 2026 December 31, 2025 Distributor A 28 % 37 % |
| DISTRIBUTOR-B |
DISTRIBUTOR-B |
92%
|
The percentages of accounts receivable trade for customers that represent 10% or more of total accounts receivable trade were as follows: March 31, 2026 December 31, 2025 Distributor B 26 % 20 % |
| DISTRIBUTOR-C |
DISTRIBUTOR-C |
92%
|
The percentages of accounts receivable trade for customers that represent 10% or more of total accounts receivable trade were as follows: March 31, 2026 December 31, 2025 Distributor C 12 % 10 % |
| MDT |
Medtronic plc |
72%
|
s are unwilling or unable to market and sell our products, do not devote adequate resources or support to generate awareness of our products and grow product sales, or if they do not perform to our e… |
| MDT |
Medtronic plc |
72%
|
Reciprocal relationship from MDT graph: Reciprocal relationship from PODD graph: Reciprocal relationship from MDT graph: Reciprocal relationship from PODD graph: s are unwilling or unable to market a… |
| AUTOMATED-GLUCOSE-CONTROL-LLC |
AUTOMATED-GLUCOSE-CONTROL-LLC |
62%
|
ock per $1,000 principal amount of the notes, which is equivalent to a conversion price of $ 226.73 per share, subject to adjustment under certain circumstances. The notes will be convertible at the … |
| BIGFOOT-BIOMEDICAL-INC |
BIGFOOT-BIOMEDICAL-INC |
62%
|
cash, cash equivalents, and restricted cash $ 249.2 $ 14.5 Operating Activities Net cash provided by operating activities of $430.3 million in 2024 was primarily attributable to net income, as adjust… |
| BSI-GROUP |
BSI-GROUP |
62%
|
providing data and insights to physicians offering diabetes care. • Providing payors with the clinical and economic justifications for why Omnipod products offer unique value to the people they insur… |
| COMPANY-INFORMATION-INSULET-CORPORATION |
COMPANY-INFORMATION-INSULET-CORPORATION |
62%
|
ugh innovative technology. All employees participate in our flagship ‘Ignite Your Growth’ career development program and as a result, establish an Individual 13 Table of Contents Development Plan, wh… |
| DIABETES-CARE-INC |
DIABETES-CARE-INC |
62%
|
bott Diabetes Care, Inc.’s (“Abbott”) FreeStyle Libre 2 Plus sensor (“Libre 2 Plus”) in various markets. Omnipod DASH features a secure Bluetooth enabled Pod that is controlled by a smartphone-like P… |
| EOFLOW-CO-LTD |
EOFLOW-CO-LTD |
62%
|
our contractual obligations as of December 31, 2024: (in millions) Short Term Long Term Total Debt obligations $ 83.8 $ 1,309.2 $ 1,393.0 Interest payments (1)(2) 46.9 211.3 258.2 Purchase obligation… |
| NEPHRIA-BIO-INC |
NEPHRIA-BIO-INC |
62%
|
Inc.; Nephria Bio, Inc.; and EOFlow’s CEO, Jesse Kim (collectively, “Defendants”), Insulet Corp. v. EOFlow Co. Ltd. et al. , 1:23-cv-11780-FDS (D. Mass.). The litigation concerned the Defendants’ mis… |
| NXP-USA-INC |
NXP-USA-INC |
62%
|
Cash provided by (used in): Operating activities $ 113.8 $ 63.8 Investing activities (27.7) (15.6) Financing activities (319.9) 277.7 Effect of exchange rate changes on cash and cash equivalents (1.9… |
| ROCHE-DIABETES-CARE-INC |
ROCHE-DIABETES-CARE-INC |
62%
|
ock per $1,000 principal amount of the notes, which is equivalent to a conversion price of $ 226.73 per share, subject to adjustment under certain circumstances. The notes will be convertible at the … |
| TANDEM-DIABETES-CARE-INC |
TANDEM-DIABETES-CARE-INC |
62%
|
providing data and insights to physicians offering diabetes care. • Providing payors with the clinical and economic justifications for why Omnipod products offer unique value to the people they insur… |
